Immune checkpoint inhibitors (ICIs) are rapidly developing immunotherapy cancer drugs that have prolonged patient survival. However, ICIs-related cardiotoxicity has been recognized as a rare, but fatal, consequence. Although there has been extensive research based on different types of ICIs, these studies have not indicated whether cardiotoxicity is specific to a type of cancer. Therefore, we conducted a systematic review to analyze a variety of ICIs-related cardiotoxicity, focusing on different types of cancer. We found that the incidence of ICIs-related cardiac adverse events (CAEs) and common cardiotoxic manifestations vary with cancer type. This inspired us to explore the underlying mechanisms to formulate targeted clinical strategies for maintaining the cardiovascular health of cancer patients.
[1]Qingdao Univ, Dept Cardiol, Affiliated Yantai Yuhuangding Hosp, Yantai 264000, Peoples R China.
[2]Qingdao Univ, Med Coll, Qingdao 266003, Peoples R China.
[3]Qingdao Univ, Dept Oncol, Affiliated Yantai Yuhuangding Hosp, Yantai 264000, Peoples R China.
[4]Tianjin Med Univ, Tianjin Inst Cardiol, Tianjin Key Lab Ion Mol Funct Cardiovasc Dis, Dept Cardiol,Hosp 2, Tianjin 300070, Peoples R China.
[5]Kent & Medway Med Sch, Canterbury CT2 7FS, Kent, England.
(8.0+极速模式)